News & Updates

KEEPsAKE findings boost risankizumab efficacy, safety for PsA
KEEPsAKE findings boost risankizumab efficacy, safety for PsA
24 Jan 2022 byAudrey Abella

In individuals with psoriatic arthritis (PsA) who have inadequate response or intolerance to ≥1 csDMARD*, the monoclonal antibody risankizumab significantly improved manifestations of PsA, according to the 24-week findings of the phase III KEEPsAKE 1 trial.

KEEPsAKE findings boost risankizumab efficacy, safety for PsA
24 Jan 2022
Hypothyroidism not associated with worse prognosis in COVID-19
Hypothyroidism not associated with worse prognosis in COVID-19
23 Jan 2022

Patients with hypothyroidism who develop COVID-19 have a lower mechanical ventilation requirement and are less likely to die in the hospital, as reported in a study.

Hypothyroidism not associated with worse prognosis in COVID-19
23 Jan 2022
Depression rife in hidradenitis suppurativa
Depression rife in hidradenitis suppurativa
23 Jan 2022

The prevalence of depression is relatively high among children, adolescents, and adults with hidradenitis suppurativa (HS), a chronic inflammatory skin disorder, according to a study, which also notes the importance of periodic screening for depression.

Depression rife in hidradenitis suppurativa
23 Jan 2022